Constantinos Tsompos1, Constantinos Panoulis2, Konstantinos Toutouzas3, George Zografos3, Apostolos Papalois4. 1. Department of Obstetrics & Gynecology, Mesologi County Hospital, Etoloakarnania, Greece. 2. Department of Obstetrics & Gynecology, Aretaieion Hospital, Greece. 3. Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Greece. 4. Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Greece.
Abstract
OBJECTIVE: The aim of this experimental study was to examine the effect of the antioxidant drug "U-74389G" on a rat model using an ischemia reperfusion protocol. The effect of U-74389G was studied biochemically by measuring mean blood creatinine levels. MATERIALS AND METHODS: Forty rats were used in the study. Creatinine levels were measured at 60 min of reperfusion (groups A and C) or at 120 min of reperfusion (groups B and D), where groups A and B were controls and groups C and D received U-74389G administration. RESULTS: U-74389G administration significantly decreased the predicted creatinine levels by 21.02 ± 5.06% (p = 0.0001). Reperfusion time non-significantly increased the predicted creatinine levels by 4.20 ± 6.12% (p = 0.4103). However, U-74389G administration and reperfusion time together produced a significant combined effect in decreasing the predicted creatinine levels by 11.69 ± 3.16% (p = 0.0005). CONCLUSION: Independent of reperfusion time, U-74389G administration significantly decreased the creatinine levels in an ischemic rat model. This study demonstrates that short-term U-74389G administration improves renal function by increasing creatinine excretion.
OBJECTIVE: The aim of this experimental study was to examine the effect of the antioxidant drug "U-74389G" on a rat model using an ischemia reperfusion protocol. The effect of U-74389G was studied biochemically by measuring mean blood creatinine levels. MATERIALS AND METHODS: Forty rats were used in the study. Creatinine levels were measured at 60 min of reperfusion (groups A and C) or at 120 min of reperfusion (groups B and D), where groups A and B were controls and groups C and D received U-74389G administration. RESULTS: U-74389G administration significantly decreased the predicted creatinine levels by 21.02 ± 5.06% (p = 0.0001). Reperfusion time non-significantly increased the predicted creatinine levels by 4.20 ± 6.12% (p = 0.4103). However, U-74389G administration and reperfusion time together produced a significant combined effect in decreasing the predicted creatinine levels by 11.69 ± 3.16% (p = 0.0005). CONCLUSION: Independent of reperfusion time, U-74389G administration significantly decreased the creatinine levels in an ischemic rat model. This study demonstrates that short-term U-74389G administration improves renal function by increasing creatinine excretion.
Authors: Dimosthenis T Chrysikos; Theodoros N Sergentanis; Flora Zagouri; Theodora Psaltopoulou; Ioannis Flessas; George Agrogiannis; Nikolaos Alexakis; Ioannis Bramis; Evgenia E Patsouri; Efstratios S Patsouris; Maria Korontzi; Angeliki Katsarou; George C Zografos; Apostolos E Papalois Journal: J Surg Res Date: 2013-11-16 Impact factor: 2.192
Authors: F O'Valle; M C Benítez; M Gómez-Morales; J Bravo; A Osuna; D Martin-Oliva; F J Oliver; R G Del Moral Journal: Transplant Proc Date: 2005-11 Impact factor: 1.066
Authors: Francine B C Lemos; Jan N M Ijzermans; Pieter E Zondervan; Annemiek M A Peeters; Sandra van den Engel; Wendy M Mol; Willem Weimar; Carla C Baan Journal: J Am Soc Nephrol Date: 2003-12 Impact factor: 10.121
Authors: Joost A B van der Hoeven; Grietje Molema; Gert J Ter Horst; Reni L Freund; Janneke Wiersema; Reinout van Schilfgaarde; Henri G D Leuvenink; Rutger J Ploeg Journal: Kidney Int Date: 2003-11 Impact factor: 10.612